Lung Cancer
Entity.
- Evidence
- 533 documents · 122 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 26 Mar 2026, last seen 2 Nov 2026
- Measured
- 6% of mentions say something specific about it; the rest only name it
- As of
- 3 Nov 2026
Where this comes from
- Daily Sabah economy · 2026-11-02 · Early diagnosis key to lung cancer treatment options: Expert (opens the source in a new tab)
- The Independent · 2026-11-01 · How Pope Leo is preparing for high altitude South America trip just weeks after lung cancer operation (opens the source in a new tab)
- Cancer Lett · 2026-11-01 · Combination of canagliflozin and adagrasib as a novel targeted therapy for LKB1-KRASG12C co-mutated NSCLC. (opens the source in a new tab)
- ascopost.com · 2026-10-30 · OptiTROP-Lung06 A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC? (opens the source in a new tab)
- The Clinical Trial Vanguard · 2026-10-30 · Iovance Adds Biomarker Selection to Lifileucel Lung Cancer Trial (opens the source in a new tab)
- Medical Daily · 2026-10-28 · Savolitinib Plus Tagrisso Added About Five Months of Median Survival Over Chemo in MET-Driven Lung Cancer (opens the source in a new tab)
- ascopost.com · 2026-10-27 · Radiation Added to Systemic Therapy Improves PFS But Not OS for Oligometastatic NSCLC (opens the source in a new tab)
- The Medical News · 2026-10-27 · Patients with a form of advanced lung cancer lived 56 percent longer without their disease progressing after receiving radiotherapy in addition to standard treatment (opens the source in a new tab)
- Targeted Oncology · 2026-10-27 · Olomorasib Combo Shows Manageable Liver Toxicity in KRAS G12C-Mutant NSCLC (opens the source in a new tab)